Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Polycystic Ovary Syndrome 2Thyroid Nodule 1Neoplasms, Adipose Tissue 1Insulin Resistance 1Diabetes Mellitus, Type 2 1Breast Neoplasms 1Body Weight 1

Interventions

Metformin 41Clomiphene 17Letrozole 6Menotropins 5Folic Acid 5drospirenone and ethinyl estradiol combination 4Liraglutide 4Chorionic Gonadotropin 4cetrorelix 3Triptorelin Pamoate 3Progesterone 3Pioglitazone 3Leuprolide 3Inositol 3Exenatide 3Ethinyl Estradiol 3Estradiol 3Vitamins 2Sperm Injections, Intracytoplasmic 2Sitagliptin Phosphate 2Simvastatin 2Gonadotropins 2Glycoprotein Hormones, alpha Subunit 2Exercise 2Escitalopram 2Cyproterone acetate, ethinyl estradiol drug combination 2Contraceptives, Oral 2Cholecalciferol 2Carnitine 2Canagliflozin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Polycystic Ovary Syndrome × Sitagliptin Phosphate × Clear all
NCT02122380 2020-05-08

The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

Vanderbilt University Medical Center

Phase 4 Completed
23 enrolled 12 charts

Polycystic Ovary Syndrome

NCT02941445 2016-10-21

Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss

University Medical Centre Ljubljana

Phase 4 Completed
24 enrolled

Body Weight, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡